Jade Biosciences, Inc. Increase (Decrease) in Accounts Payable
Jade Biosciences, Inc. (JBIO) reported Increase (Decrease) in Accounts Payable of $4.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- Jade Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $2.10M, a 7.12% decline year-over-year.
- Jade Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.33M, a 13.04% decline year-over-year.
- Jade Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $301.00K, a 69.66% decline year-over-year.
- Jade Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$4.88M, a 1736.91% decline year-over-year.
- Jade Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2025 was $361.00K.
- Jade Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$2.17M.
- Jade Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$164.00K, a 111.99% decline from fiscal 2022.
- Jade Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.37M, a 124.63% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.43M 10-Q · filed 2026-08-10 | $4.73M derived: sum of 3 quarters · filed 2026-08-10 | -$149.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $2.33M 10-Q · filed 2026-05-07 | $2.63M derived: sum of 2 quarters · filed 2026-05-07 | -$2.25M derived: sum of 3 quarters · filed 2026-05-07 | $12.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $301.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$4.58M derived: sum of 2 quarters · filed 2026-03-06 | -$2.32M derived: sum of 3 quarters · filed 2026-08-10 | $361.00K 10-K · filed 2026-03-06 | |
| 2025-09-30 | -$4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.62M derived: sum of 2 quarters · filed 2026-08-10 | $60.00K 10-Q · filed 2025-11-14 | $1.05M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.94M 10-Q · filed 2026-08-10 | $5.93M derived: sum of 3 quarters · filed 2026-08-10 | $6.23M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $2.68M 10-Q · filed 2026-05-07 | -$155.00K 10-Q · filed 2025-04-25 | $3.67M derived: sum of 2 quarters · filed 2026-05-07 | $3.97M derived: sum of 3 quarters · filed 2026-05-07 | $4.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $992.00K derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | $1.29M 10-K · filed 2026-03-06 | $2.24M derived: sum of 3 quarters · filed 2026-03-06 | -$2.17M 10-K · filed 2025-03-27 | |
| 2024-09-30 | $298.00K 10-Q · filed 2025-11-14 | $1.25M derived: sum of 2 quarters · filed 2025-11-14 | -$1.49M 10-Q · filed 2024-11-12 | $1.04M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $948.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.78M 10-Q · filed 2024-08-12 | $739.00K derived: sum of 3 quarters · filed 2025-04-25 | -$1.27M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | $835.00K 10-Q · filed 2025-04-25 | -$209.00K derived: sum of 2 quarters · filed 2025-04-25 | -$2.22M derived: sum of 3 quarters · filed 2025-04-25 | -$1.45M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2023-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$3.06M derived: sum of 2 quarters · filed 2025-03-27 | -$2.29M derived: sum of 3 quarters · filed 2025-03-27 | -$164.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.24M derived: sum of 2 quarters · filed 2024-11-12 | $880.00K 10-Q · filed 2024-11-12 | -$869.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $773.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.89M 10-Q · filed 2024-08-12 | $1.15M derived: sum of 3 quarters · filed 2024-08-12 | $3.39M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $2.12M 10-Q · filed 2024-05-13 | $372.00K derived: sum of 2 quarters · filed 2024-05-13 | $2.61M derived: sum of 3 quarters · filed 2024-05-13 | $1.90M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $493.00K derived: sum of 2 quarters · filed 2024-03-25 | -$219.00K derived: sum of 3 quarters · filed 2024-03-25 | $1.37M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.53M derived: sum of 2 quarters · filed 2023-11-13 | $3.12M 10-Q · filed 2023-11-13 | $2.07M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$712.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $875.00K 10-Q · filed 2023-08-14 | -$170.00K derived: sum of 3 quarters · filed 2023-08-14 | $921.00K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $1.59M 10-Q · filed 2023-05-15 | $542.00K derived: sum of 2 quarters · filed 2023-05-15 | $1.63M derived: sum of 3 quarters · filed 2023-05-15 | $1.43M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $46.00K derived: sum of 2 quarters · filed 2023-03-29 | -$156.00K derived: sum of 3 quarters · filed 2023-03-29 | $609.00K 10-K · filed 2023-03-29 | |
| 2021-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $889.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.65M 10-Q · filed 2022-11-14 | $1.66M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $563.00K 10-Q · filed 2022-08-15 | $570.00K derived: sum of 3 quarters · filed 2022-08-15 | $471.00K derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $765.00K 10-Q · filed 2022-05-16 | $772.00K derived: sum of 2 quarters · filed 2022-05-16 | $673.00K derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$92.00K derived: sum of 2 quarters · filed 2022-03-30 | $37.00K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | -$99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $30.00K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $129.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |